PolymyositisSymptoms, Doctors, Treatments, Advances & More
Polymyositis Overview
Learn About Polymyositis
- Polymyositis
Johns Hopkins Bayview Medical Center
Andrew Mammen is a Neuromusculoskeletal Medicine specialist and a Neurologist practicing medicine in Baltimore, Maryland. Dr. Mammen is rated as an Elite provider by MediFind in the treatment of Polymyositis. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Myositis, Polymyositis, Dermatomyositis, and Necrotizing Myopathy (NM). Dr. Mammen is board certified in American Board Of Psychiatry And Neurology.
Johns Hopkins Bayview Medical Center
Dr. Julie Paik completed her medical school training at the George Washington University School of Medicine in Washington, DC. She then completed her residency and chief residency at UCLA-Cedars-Sinai/VA Medical Center in Los Angeles, California. She completed rheumatology fellowship at Johns Hopkins and joined the faculty in 2013. She currently sees patients at the Johns Hopkins Myositis Center and Scleroderma Center. Her research interests are in myositis and scleroderma or overlap myositis. She also has a special interest in novel therapeutics in refractory dermatomyositis. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Paik is rated as an Elite provider by MediFind in the treatment of Polymyositis. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Dermatomyositis, Polymyositis, Myositis, and Scleroderma. Dr. Paik is board certified in American Board Of Internal Medicine.
UPMC Arthritis And Autoimmunity Center
Chester V. Oddis, MD is a noted researcher in the clinical, epidemiological and serologic description of the idiopathic inflammatory myopathies. He has completed epidemiological studies on the incidence of polymyositis and dermatomyositis as well as longitudinal studies on functional disability in myositis patients. His focus has been in the autoantibody patterns in patients with inflammatory myopathy and their peculiar immunogenetic associations.Dr. Oddis has written extensively on the diagnosis and management of patients with myositis. He has published and lectured on the use of novel immunosuppressive agents such as tacrolimus (formerly FK506) in the treatment of patients with refractory myositis. This represents the only reported experience of this particular drug in the pharmacologic treatment of inflammatory myopathy. In collaboration with the Department of Neurology, he has assessed the efficacy and utility of outpatient needle muscle biopsy in the diagnosis of inflammatory myopathy. This is important given the cost-containment focus of the current health-care market.Dr. Oddis is the co-investigator on an important national NIH funded study on the efficacy of doxycycline in preventing the progression of knee osteoarthritis in middle-aged women. This study is the first of its kind in assessing the effect of a disease-modifying agent in osteoarthritis.Board certified in internal medicine and rheumatology, Dr. Oddis received his medical degree from Pennsylvania State University, Milton S. Hershey Medical Center and his undergraduate degree from the University of Pittsburgh. He completed his residency in internal medicine at Penn State and fellowship at the University of Pittsburgh Medical Center. Dr. Oddis is rated as an Elite provider by MediFind in the treatment of Polymyositis. He is also highly rated in 12 other conditions, according to our data. His clinical expertise encompasses Myositis, Dermatomyositis, Polymyositis, and Antisynthetase Syndrome. Dr. Oddis is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Oddis is currently accepting new patients.
Objective: To see if omega-3 fatty acid supplements from fish oil, combined with a healthy diet, can help people with DM/JDM.
Summary: This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (ad...
Published Date: May 13, 2022
Published By: Genetic and Rare Diseases Informnation Center


